Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Kwon

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Military Medicine|May 14, 2024
Revolutionizing Combat Casualty Care: The Power of Digital Twins in Optimizing Casualty Care Through Passive Data CollectionJeremy C Pamplin, Mason H Remondelli, Darshan Thota, et al.
Journal of Clinical Pharmacology|January 7, 2006
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasisAmita Joshi, Robert Bauer, Peter Kuebler, et al.
International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.
International Journal of Cancer|February 4, 2010
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistanceWenlin Shao, Joseph D Growney, Yun Feng, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
Dermatology (Basel, Switzerland)|October 13, 2006
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasisCraig L Leonardi, Darryl Toth, Jennifer C Cather, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
Journal of Medicinal Chemistry|February 8, 2002
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamatesStacy W Remiszewski, Lidia C Sambucetti, Peter Atadja, et al.
Journal of the American Academy of Dermatology|September 22, 2019
Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trialAlbert S Chiou, Sara Choi, Melissa Barriga, et al.
Journal of Global Antimicrobial Resistance|November 16, 2019
Comparative genomic analysis of four multidrug-resistant isolates of Acinetobacter baumannii from GeorgiaJason Farlow, Maia Nozadze, Nino Mitaishvili, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Military Medicine|May 14, 2024
Revolutionizing Combat Casualty Care: The Power of Digital Twins in Optimizing Casualty Care Through Passive Data CollectionJeremy C Pamplin, Mason H Remondelli, Darshan Thota, et al.
Journal of Clinical Pharmacology|January 7, 2006
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasisAmita Joshi, Robert Bauer, Peter Kuebler, et al.
International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.
International Journal of Cancer|February 4, 2010
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistanceWenlin Shao, Joseph D Growney, Yun Feng, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
Dermatology (Basel, Switzerland)|October 13, 2006
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasisCraig L Leonardi, Darryl Toth, Jennifer C Cather, et al.
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part IDavid M Pariser, Kenneth B Gordon, Kim A Papp, et al.
Journal of Medicinal Chemistry|February 8, 2002
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamatesStacy W Remiszewski, Lidia C Sambucetti, Peter Atadja, et al.
Journal of the American Academy of Dermatology|September 22, 2019
Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trialAlbert S Chiou, Sara Choi, Melissa Barriga, et al.
Journal of Global Antimicrobial Resistance|November 16, 2019
Comparative genomic analysis of four multidrug-resistant isolates of Acinetobacter baumannii from GeorgiaJason Farlow, Maia Nozadze, Nino Mitaishvili, et al.
Pageof 4